EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Top-Down Proteomics Identifies Plasma Proteoform Signatures of Liver Cirrhosis Progression

Eleonora Forte, Jes M Sanders, Indira Pla, Vijaya Lakshmi Kanchustambham, Michael A R Hollas, Che-Fan Huang, Aniel Sanchez, Katrina N Peterson, Rafael D Melani, Alexander Huang, Praneet Polineni, Julianna M Doll und 3 weitere

Molecular & Cellular Proteomics · 2024-12 · 23 (12) · 100876

DOI: 10.1016/j.mcpro.2024.100876 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular & Cellular Proteomics, 2024-12. Verfasst von Eleonora Forte und 14 weiteren Autor:innen. Beteiligte Einrichtung: Proteomics Center of Excellence, Northwestern University, Evanston, Illinois, USA; Northwestern University Transplant Outcomes Research Collaborative…. Hauptthemen laut MEDLINE: Liver Cirrhosis, Proteomics, Disease Progression, Biomarkers. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, National Institute of General Medical Sciences, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cirrhosis, advanced liver disease, affects 2 to 5 million Americans. While most patients have compensated cirrhosis and may be fairly asymptomatic, many decompensate and experience life-threatening complications such as gastrointestinal bleeding, confusion (hepatic encephalopathy), and ascites, reducing life expectancy from 12 to less than 2 years. Among patients with compensated cirrhosis, identifying patients at high risk of decompensation is critical to optimize care and reduce morbidity and mortality. Therefore, it is important to preferentially direct them towards specialty care which cannot be provided to all patients with cirrhosis. We used discovery top-down proteomics to identify differentially expressed proteoforms (DEPs) in the plasma of patients with progressive stages of liver cirrhosis with the ultimate goal to identify candidate biomarkers of disease progression. In this pilot study, we identified 209 DEPs across three stages of cirrhosis (compensated, compensated with portal hypertension, and decompensated), of which 115 derived from proteins enriched in the liver at a transcriptional level and discriminated the three stages of cirrhosis. Enrichment analyses demonstrated DEPs are involved in several metabolic and immunological processes known to be impacted by cirrhosis progression. We have preliminarily defined the plasma proteoform signatures of cirrhosis patients, setting the stage for ongoing discovery and validation of biomarkers for early diagnosis, risk stratification, and disease monitoring.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver CirrhosisProteomicsDisease ProgressionBiomarkersHumansMaleFemaleMiddle AgedAgedProteomeBlood ProteinsAdultPilot Projects

Stichwörter der Autor:innen

LC-MS/MSapo A-Ifibrinogen alpha chainhaptoglobinliver cirrhosismass spectrometryproteoformstop-down proteomics

Substanzen

BiomarkersProteomeBlood Proteins

Autor:innen und Institutionen

  • Proteomics Center of Excellence, Northwestern University, Evanston, Illinois, USA; Northwestern University Transplant Outcomes Research Collaborative (NUTORC), Comprehensive Transplant Center, Feinberg School of Medicin…
  • Northwestern University Transplant Outcomes Research Collaborative (NUTORC), Comprehensive Transplant Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
  • Proteomics Center of Excellence, Northwestern University, Evanston, Illinois, USA.
  • Proteomics Center of Excellence, Northwestern University, Evanston, Illinois, USA; Department of Chemistry, Northwestern University, Evanston, Illinois, USA; Department of Biochemistry and Molecular Genetics, Northweste…
  • Northwestern University Transplant Outcomes Research Collaborative (NUTORC), Comprehensive Transplant Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA. Electronic address: dladner@nm.…

Förderung

  • NIDDK NIH HHS
  • National Institute of General Medical Sciences
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Institutes of Health
  • Northwestern University Feinberg School of Medicine

Zitieren

APA

Forte, E., Sanders, J. M., Pla, I., Kanchustambham, V. L., Hollas, M. A. R., Huang, C. F., Sanchez, A., Peterson, K. N., Melani, R. D., Huang, A., Polineni, P., Doll, J. M., Dietch, Z., Kelleher, N. L., & Ladner, D. P. (2024). Top-Down Proteomics Identifies Plasma Proteoform Signatures of Liver Cirrhosis Progression. Molecular & Cellular Proteomics, 23(12), 100876. https://doi.org/10.1016/j.mcpro.2024.100876

Vancouver

Forte E, Sanders JM, Pla I, Kanchustambham VL, Hollas MAR, Huang CF, et al. Top-Down Proteomics Identifies Plasma Proteoform Signatures of Liver Cirrhosis Progression. Molecular & Cellular Proteomics. 2024;23(12):100876. doi:10.1016/j.mcpro.2024.100876

BibTeX
@article{Forte2024,
  author = {Forte, Eleonora and Sanders, Jes M and Pla, Indira and Kanchustambham, Vijaya Lakshmi and Hollas, Michael A R and Huang, Che-Fan and Sanchez, Aniel and Peterson, Katrina N and Melani, Rafael D and Huang, Alexander and Polineni, Praneet and Doll, Julianna M and Dietch, Zachary and Kelleher, Neil L and Ladner, Daniela P},
  title = {Top-Down Proteomics Identifies Plasma Proteoform Signatures of Liver Cirrhosis Progression},
  journal = {Molecular & Cellular Proteomics},
  year = {2024},
  volume = {23},
  number = {12},
  pages = {100876},
  doi = {10.1016/j.mcpro.2024.100876}
}
Kostenlos starten →